Cargando…
IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416483/ https://www.ncbi.nlm.nih.gov/pubmed/36033902 http://dx.doi.org/10.2147/OTT.S386447 |
| _version_ | 1784776491485102080 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9416483 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94164832022-08-27 IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] Onco Targets Ther Retraction Dove 2022-08-22 /pmc/articles/PMC9416483/ /pubmed/36033902 http://dx.doi.org/10.2147/OTT.S386447 Text en © 2022 Dove Medical Press. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Retraction IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title_full | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title_fullStr | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title_full_unstemmed | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title_short | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction] |
| title_sort | il-6/stat3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells [retraction] |
| topic | Retraction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416483/ https://www.ncbi.nlm.nih.gov/pubmed/36033902 http://dx.doi.org/10.2147/OTT.S386447 |